Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
So be careful
Within the past six years alone, four ADCs have been approved for urogenital malignancies: enfortumab vedotin for urothelial carcinoma, tisotumab vedotin for cervical cancer, and mirvetuximab soravtansine for ovarian and fallopian tube cancers 8
Research progress of Ti-EVs in tumors Currently, Ti-EVs used in tumor diagnosis and treatment research are mainly derived from tumor and adipose tissue
The aberrant activation of self-reactive T-cells and drug-specific T cells The initiation of ICIs can result in the abnormal activation of tissue-specific self-reactive T cells, potentially disrupting or compromising immune tolerance to renal self-antigens
L-Carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis
US$ 21.64
US$ 21.52
US$ 25.73
US$ 28.96
US$ 24.45
US$ 24.51
US$ 21.99
US$ 22.12
US$ 23.84
/assets/images/provider/photos/2749086.jpeg)
